FATI-유니콘뉴스

뉴스기사물 (10)

2024-08-22 00:00:28

방송 세종--(뉴스와이어)--농림수산식품교육문화정보원(원장 이종순, 이하 농정원)이 ‘국내 여행 및 농촌여행 트렌드’를 주제로 온라인 언급량과 키워드를 비교 분석한 ‘FATI (Farm Trend&Issue)’ 보고서 17호를 발표했다. 국내 여행 트렌드 관련...

2024-07-31 00:00:20

Shoppers in Asia embrace change: NIQ 2024 Shopper Trends report unveils five key trends shaping the future of grocery shopping

SINGAPORE--(Business Wire / Korea Newswire)--The grocery landscape in Asia is undergoing a dynamic transformation, driven by evolving consumer values and economic realities. The 2024 Shopper Trends report by NIQ, a leading authority in consumer...

2024-07-05 00:00:54

Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323

TOKUSHIMA, JAPAN--(Business Wire / Korea Newswire)--We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination...

2024-07-05 00:00:54

델타플라이파마, DFP-14323의 제3상 확증 비교 임상시험에 환자 등록 개시 고지

건강제약해외 도쿠시마, 일본--(Business Wire / 뉴스와이어)--델타플라이파마(Delta-Fly Pharma Inc.)가 임상 개발에 대한 최신 소식을 발표했다. 델타플라이파마는 2024년 2월 의약품의료기기종합기구(PMDA)의 승인을 받은 ‘일반적이지 않은 EGFR 변이 양성이 있는 3/4기 비소세포폐암 환자를 대상으로 아파티닙(40mg/일) 단독 투여와 DFP-14323과 아파티닙(20mg/일)의...

2024-07-03 00:00:23

디노도 ‘디노도 플랫폼 9.0’ 출시… AI 기반 지능형 데이터 관리 방식으로 데이터 혁신 가속화

서울인터넷인공지능 서울--(뉴스와이어)--데이터 관리 분야 글로벌 선도기업 디노도테크놀로지(이하 디노도)가 2일 새롭게 업데이트된 ‘디노도 플랫폼(Denodo Platform) 9.0’을 출시한다고 밝혔다. 디노도 로고 디노도 플랫폼...

2024-06-28 00:03:30

NetApp Earns AAA Rating for Industry-First AI-Driven On-Box Ransomware Detection Solution

SAN JOSE, CALIF--(Business Wire / Korea Newswire)--NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) has received a AAA rating from SE Labs,...

2024-06-26 00:00:36

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

OSAKA, JAPAN & CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that...

2024-06-24 00:00:04

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

제약 OSAKA, JAPAN & CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer...

2024-06-21 00:00:06

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

사회공헌기업 경영 OSAKA, JAPAN & CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin...

2024-06-03 00:00:14

Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024

CRANBURY, N.J.--(Business Wire / Korea Newswire)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive /...

API